Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. - Wikidata - awgldk - TriplyDB

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

http://www.wikidata.org/entity/Q37383449

about

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin Aggressive variants of castration-resistant prostate cancer Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.Integrative molecular profiling of routine clinical prostate cancer specimens.SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Markers for detection of prostate cancer.HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey Nutrigenetics and prostate cancer: 2011 and beyond.Histological variants of prostatic carcinoma and their significance.ERG protein expression as a biomarker of prostate cancer.Small cell carcinoma of the prostate.Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate Ductal adenocarcinoma of the prostate: Clinical and biological profiles.The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.Emerging Variants of Castration-Resistant Prostate Cancer.Potential for targeted therapy in prostate cancers with ERG abnormalities.TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens ERG gene rearrangements are common in prostatic small cell carcinomas.Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.Mucinous and secondary tumors of the prostate.SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.Neuroendocrine tumors of the prostate.Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.ERG rearrangement is present in a subset of transition zone prostatic tumors Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer

P2860

Q31005436-F9215758-D99A-46F9-A596-5660321DD057 Q33693256-C8016B23-51B7-4E4E-9338-D9DF31CB1253 Q34158217-02A9CE57-E926-44C4-8CA4-606E5E2CB734 Q34411717-5DAE1863-8461-410A-A163-AEFA51A4563C Q35892022-77C721EC-2A10-4133-B446-D6CABEF41490 Q35983468-382FDB10-6852-4BCD-AF10-E38B55A1A2AB Q36131601-62DD6534-F464-4C37-9F08-8E4E34E9635C Q36147719-94E12168-47FA-4BE8-9496-D9A26E1A8433 Q36901964-F4519F04-1A5A-421C-9190-CA9243194C84 Q37328403-13DB1D12-C8B2-4E2F-9F98-99CCEE58DBF5 Q37705596-FDEFA16F-9B0E-4C0A-8D0B-5B4D95DFE023 Q37885642-4DC42481-9A7A-4364-979B-795E4F67676D Q37972700-5AA8BE56-8D97-45A0-8D7E-ACF3EF17E24B Q38165243-61E774B8-87A6-42F5-8B24-6A47E18C3119 Q38188869-2C711526-7DE9-45FB-978C-AE113418D769 Q38377884-0CF48314-884C-4E3C-8388-601B724E968C Q38683009-D1D1339D-4834-47ED-96D3-2CA4D50F76C7 Q38929364-B5BA1A88-49D5-4F09-8A48-85E7C8C8F7BC Q38930155-602D8908-96CD-436F-9CFF-59630E678FCD Q39033577-1B772461-F12C-402E-981A-2F9424C67CE2 Q39210257-4CFE9BA5-8301-4189-AC47-6DF7A1985317 Q39501622-7C9D7469-A1BF-4004-8F4E-69D028E533F5 Q39577718-0A802A17-2054-4E27-89EF-48C0F95AAF80 Q39666134-8D13A883-7976-43F8-9EE5-F73BB5A9EB14 Q41052383-E33D1E8A-2183-4876-A0EC-706987DE1A63 Q41628946-732DC7E8-E766-4A9A-91AA-07026CD34229 Q42184220-27FF9AC9-B63E-4AD9-B909-493CE42C0015 Q43247408-C01E0B55-4481-464C-AA49-A3BABBED186D Q47288076-C551161C-ED4D-4564-BEB2-B8F6FA7106C0 Q47664729-CDD4E11D-79A0-47DF-AF76-463C094F55A1 Q48030483-0DC83B80-638B-4890-99DE-32DFEEB41B8B Q49347811-43867196-D5FC-4903-8DFD-1DDBE6B62968 Q51495262-1EB005AC-6CF3-49B8-B3E3-D737235728CB Q54403866-C7986F31-6209-46C2-B382-A7350E619EE4 Q57693373-E9D83FD9-591A-4BCE-AE21-CDCD34475F5A Q57790298-372E5A6B-C1EF-4A4F-A2B8-59FC52EAD92B

P2860

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

http://www.wikidata.org/entity/Q37383449

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@en

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@nl

type

label

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@en

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@nl

prefLabel

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@en

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@nl

P1433

Q37383449-CE71271C-C02D-4D67-84DA-13D41A992BD4

P1476

Q37383449-4B96C401-57BA-4421-A353-1264DD50170B

P2093

Q37383449-19197749-5744-4FA1-A620-EE48278AA534

Q37383449-34E170DC-1392-4C8C-84FF-6C4522E615D0

Q37383449-3510F0D3-97AA-4CEA-9E20-35C9A2DA424C

Q37383449-4A065B09-3F30-473B-AED4-4B43BC6F027B

Q37383449-7C232326-4D4D-4B25-A7A9-F028013513BF

Q37383449-80D2017C-AFF5-407B-8308-88D0723C992B

Q37383449-96CE4B0A-1F3F-4514-9868-B34445EB19F7

Q37383449-D1B0F398-F290-416B-AB2C-7865F08576A6

Q37383449-DD153466-1622-49DC-9DFC-246A44EC22F1

Q37383449-F2395C5A-F52E-4B7F-885D-A68FA165C246

P2860

Q37383449-03DAD714-AD1E-457A-B10B-2AAE0BF225BF

Q37383449-065F21F9-E1A9-4656-8358-496EA9EB9495

Q37383449-094382B5-EAC7-42D3-8B2B-464475ED7E9A

Q37383449-09D110AC-6401-42BB-8F4B-AB658A920E12

Q37383449-2E54E0C8-5F66-431C-8488-BBDADF7FB428

Q37383449-30A71452-AFE9-4AA2-98B5-D6C86726DD65

Q37383449-3EF09898-8601-4F4A-B520-513A039DDB76

Q37383449-3FFB7E69-C1B3-4EC1-9716-97933D8E3BF0

Q37383449-417F7D69-895F-47FC-B043-1D5356EA7241

Q37383449-41ACCAD8-6884-4C86-8882-DBC2F66E2CEE

P2888

Q37383449-7A3CFA12-533D-4373-8057-D7799F140525

P304

Q37383449-29D06FD5-4D60-4D6B-920C-9567EB5CEF22

P31

Q37383449-D4F67369-EC4C-4701-9D1B-D16376205A7C

P356

Q37383449-0BF51A00-8B46-42C1-95ED-5A5152D16B69

P433

Q37383449-3693A318-8A77-4172-A623-7F2CF5F2190C

P478

Q37383449-56244D11-9CAD-4062-A556-2EF4386C300D

P50

Q37383449-0E8208ED-9EBB-4C17-8F68-B73E74EBDAE2

P577

Q37383449-E4BFCD43-2F04-4D26-8B1A-7BD2122B1C71

P5875

Q37383449-C84DA44F-B64F-4202-94BB-C5810C64DB17

P6179

Q37383449-EE15CFCC-4771-4761-B301-A1265109186C

P698

Q37383449-76EED6D6-B027-4BDE-B572-F56AEBE09AD8

P932

Q37383449-8D30DDB0-5D52-4DFE-91B1-B7B000FDBBA1

P356

MODPATHOL.2009.79

P1433

Modern Pathology

P1476

Characterization of ETS gene a ...... ariants of prostate carcinoma.

@en

P2093

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Bo Han

http://www.w3.org/2001/XMLSchema#string

Katherine A Linetzky

http://www.w3.org/2001/XMLSchema#string

Khalid Suleman

http://www.w3.org/2001/XMLSchema#string

Lei Wang

http://www.w3.org/2001/XMLSchema#string

Ming Zhou

http://www.w3.org/2001/XMLSchema#string

Nishi Singhal

http://www.w3.org/2001/XMLSchema#string

Rajal B Shah

http://www.w3.org/2001/XMLSchema#string

Rohit Mehra

http://www.w3.org/2001/XMLSchema#string

Scott A Tomlins

http://www.w3.org/2001/XMLSchema#string

P2860

The role of SPINK1 in ETS rearrangement-negative prostate cancers

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

The pathology of familial breast cancer: Morphological aspects.

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Cancer statistics, 2008

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Combined small-cell carcinoma of the stomach: p53 and K-ras gene mutational analysis supports a monoclonal origin of three histological components.

Integrative molecular concept modeling of prostate cancer progression.

Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance.

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

P2888

modpathol.2009.79

P304

1176-1185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2009.79

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Nallasivam Palanisamy

P577

2009-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26237469

http://www.w3.org/2001/XMLSchema#string

P6179

1029125989

http://www.w3.org/2001/XMLSchema#string

P698

19465903

http://www.w3.org/2001/XMLSchema#string

P932

2760291

http://www.w3.org/2001/XMLSchema#string